Grant ID RP170079
Awarded On November 16, 2016
Title Palbociclib synergizes with autophagy inhibitors to induce senescence in breast cancer
Program Academic Research
Award Mechanism Individual Investigator
Institution/Organization The University of Texas M.D. Anderson Cancer Center
Principal Investigator/Program Director Khandan Keyomarsi
Cancer Sites Breast
Contracted Amount $900,000
Lay Summary

Newer strategies are needed for the treatment of advanced hormone receptor-positive/HER2-negative breast cancer; the subtype associated with the greatest number of cancer deaths. While agents such as mTOR and CDK 4/6 blockade can delay progression when added to hormonal therapy, no improvement in survival has been observed. Virtually all patients eventually exhibit progression and about one third never respond, or progress within less than 4-6 months. The use of the approved CDK 4/6 inhibitor, palbociclib (PD), also results in neutropenia, necessitating treatment delay or discontinuation. Also, there are no predictive biomarkers to identify tumors with intrinsic and/or acquired resistan...

Read More